Biological effects of γ-interferon on human tumor cells: Quantity and affinity of cell membrane receptors for γ-IFN in relation to growth inhibition and induction of HLA-DR expression-Reference-Cited by-同舟云学术

Biological effects of γ-interferon on human tumor cells: Quantity and affinity of cell membrane receptors for γ-IFN in relation to growth inhibition and induction of HLA-DR expression

Published:1985-07-15 Issue:1 Volume:36 Page:103-108
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ücer Ugur,Bartsch Helge,Scheurich Peter,Pfizenmaier Klaus

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci

2. Human interferon-gamma is internalized and degraded by cultured fibroblasts.

3. , and , Receptor binding and endocytosis of purified human interferon-gamma (IFNγ). In: , and , (ed.). Interleukins, lymphokines, and cytokines. Proceedings of the Third International Lymphokine Workshop, pp. 553–558, Academic Press, New York/London (1983b).

4. Recombinant Gamma Interferon Induces HLA-DR Expression on Cultured Human Keratinocytes

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression;World Journal of Clinical Oncology;2024-02-24

2. ヒト由来培養がん細胞を用いた薬物代謝酵素シトクロムP-450分子種等の変動要因に関する研究～エピジェネティクス関連事象や細胞の三次元的培養環境を中心に～;YAKUGAKU ZASSHI;2023-12-01

3. Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway;Biomedicine & Pharmacotherapy;2022-11

4. Identification of Type II Interferon Receptors in Geese: Gene Structure, Phylogenetic Analysis, and Expression Patterns;BioMed Research International;2015

5. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy;International Immunopharmacology;2014-10